masthead-publications

Categories

Filter by Topics

ADCC Gene Alteration ALK Angiogenesis Anti-TNF Alpha Therapy Apoptosis Asthma Autocrine Signaling Autoimmune Disorder Biofluid Biology of neoplasia Biomarkers Bladder Brain Breast Cancer CDKN2A mutation Cells Cerebrospinal Fluid Childhood Atopic Dermatitis Chronic Obstructive Pulmonary Disease Circulating miRNAs cMET Colorectal cancer Comparison study Core Needle Biopsy Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT Encephalophy Epstein-Barr ERBB3 Esophageal Cancer Exosomes Extracellular Vesicles Fabry Disease FFPE FGF Ligand Trap FGFR Fibrous Tumors Gene Fusions Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HLA-E HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune Tolerance Immune-related Colitis Immuno-Oncology Immunotherapy Inflammation Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver Lung Lupus Lymph Node Metastasis Lymphoma Mechanism of Action Melanoma Mesothelioma MET Microenvironment miRNA Molecular Characterization Mouse mRNA custom mTOR pathway Multiple Myeloma Muscle Mutations MYC NAFLD Nash and Fibrosis Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic non-Hodgkin Lymphoma Novel Therapeutic Targets NTRK1 Oesophageal Adenocarcinoma Oncology Oral Cancer Osteoclast Ovarian cancer Pancreas Paralysis Parkinson's Disease Pathogenesis Pathway Analysis PBMCs PCA Cell Lines PIK3CA mutation Plasma Platform Comparison Predictive Modeling Programmed cell death protein 1 Progression free-survival Prostate qNPA qPCR Radioimmunotherapy Rearrangements Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma Serum Signaling Inhibitors Signatures Sinonasal Undifferentiated Carcinoma SPECS Lung Consortium Squamous cell carcinoma Sub-typing Surveillance Survival Outcomes Survival plots Synovial Fluid Therapeutic Response Therapeutic targets TMB Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes Urothelial carcinoma VEGFR Xenograft Tissue

2020

Small Cell Lung Cancer Neuroendocrine Subtypes are Associated with Different Immune Microenvironment and Checkpoint Molecule Distribution

Dora, D., et al. Small Cell Lung Cancer Neuroendocrine Subtypes are Associated with Different Immune Microenvironment and Checkpoint Molecule Distribtution. bioRxiv preprint 2020 Feb 3. doi:https://doi.org/10.1101/2020.02.02.930305

Download pdf 3.4MB

Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Woment with Treatment-Naïve Metastatic Breast Cancer

Finn, R. S., et al. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Woment with Treatment-Naïve Metastatic Breast Cancer. Clinical Cancer Research | Precision Medicine and Imaging. 2020 Jan 15. 26:110-21. DOI: 10.1158/1078-0432.CCR-19-0751.

Download pdf 1.4MB

2019

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Younes, A., et al. Journal of Clinical Oncology 2019 Mar22;37(15):1285-1295. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Download pdf 1.2MB

Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)

Martin, M., et al., Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). Paper presented at San Antonio Breast Cancer Symposium; 2019 December 10-14; San Antonio, Texas. Session GS2.

Download pdf 1.1MB

Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with baseline Metabolic Tumor volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial.

Richter, J., et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Blood Cancer Journal 2019 Aug 19; 9(67).

Download pdf 757KB

Transcriptomic and Protein Analysis of Small-cell Baldder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.

Koshkin, V. S., et al. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer  Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clinical Cancer Research. 2019 Jan 1; 25(1) 210-221.

Download pdf 7.4MB

2018

Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples.

Schaffer, M., et al. Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples. J Mol Biomark Diagn 2018, 9:2 DOI: 10.4172/2155-9929.1000386

Download pdf 1.3MB

Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3.

Finn, R. S., et al. Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3. Abstract presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; 2018  Jun 2; Chicago, IL. 

View External Link

Cell-of-origin classification of diffuse large B-cell lymphoma - comparison of molecular tests and extension to the PETAL trial

Richter, J. et al, Cell-of-origin classification of diffuse large B-cell lymphoma - comparison of molecular tests and extension to the PETAL trial. Abstract presented at: 102nd Annual Meeting of the German Society for Pathology 2018 May 24 – 16; Berlin, Germany Abstract, #AG02.16

Download pdf 121KB

2017

Comprehensive Gene Expression Biomarker Analysis of Cyclin-Dependent Kinases 4/6 and Endocrine Pathways from the PALOMA-2 Study

Finn, R. S. et al. Comprehensive Gene Expression Biomarker Analysis of Cyclin-Dependent Kinases 4/6 and Endocrine Pathways From the PALOMA-2 Study. Poster session presented at: San Antonio Breast Cancer Symposium (SABC); 2017 Dec 5-9; San Antonio, TX.

Download pdf 345KB

Page last updated June 29, 2020